Semaglutide is ideally suited for adults who are obese or overweight, either with a body mass index (BMI) over 30, or a BMI of 2530 and at least one other complication that is related to body weight, such as insulin resistance, glucose intolerance, type 2 diabetes, high blood pressure, high cholesterol, hypertension, sleep apnea, arthritis, or cardiovascular disease
1995 Mar
'Dangerous' tanning products promoted by influencers Published Dozens of social-media influencers are promoting banned tanning products to millions of followers, a BBC News investigation has found
Morrow: You actually don't need a referral from your doctor
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism